Relationship Between Gout Flare States and Patient-Reported Outcomes After Allopurinol Initiation

Area of Science:

• Rheumatology
• Clinical Medicine
• Patient-Reported Outcomes

Background:

• Gout flares are a primary clinical manifestation of gout.
• Patient-acceptable symptom state (PASS) and low disease activity (LDA) are defined by flare frequency.
• Understanding the impact of flare states on patient-reported outcomes is crucial for disease management.

Purpose of the Study:

• To investigate the relationship between gout flare states (PASS, LDA, non-LDA/PASS) and patient-reported outcomes.
• To assess the impact of flare burden on health-related quality of life and illness perception in gout patients.

Main Methods:

• Post hoc analysis of a 12-month randomized controlled trial (n=172) comparing colchicine and allopurinol.
• Monthly collection of self-reported gout flares.
• Assessment of Health Assessment Questionnaire (HAQ), EuroQol 5-domain (EQ-5D-3L), and Brief Illness Perception Questionnaire (BIPQ) at specified intervals.

Main Results:

• In the latter six months, 38% achieved PASS, 19% LDA, and 43% were non-LDA/PASS.
• No significant association was found between flare states and EQ-5D-3L or HAQ scores.
• A significant association was observed between flare states and three Brief Illness Perception Questionnaire (BIPQ) items: consequences, identity, and concern.

Conclusions:

• Most patients can achieve PASS or LDA within six months of initiating allopurinol.
• Higher gout flare burden correlates with increased negative impact on patients.
• Prioritizing gout flare prevention is essential for improving patient outcomes and quality of life.